Fig. 8.

Schematic of a plausible model for the promoted efficacy from Eu-FBCP/PTX-induced ICD by incorporating Eu-FBCP/PTX with aPL. The Eu-FBCP/PTX entered the tumor cells through both phagocytosis and micropinocytosis for releasing PTX, inducing the G2/M phase in the cell cycle and intrinsic apoptosis. The apoptotic cancer cells significantly released HMGB1 and CRT that drove DC maturation and CD8⁺ T cell activation. This ICD induced by Eu-FBCP-PTX further facilitated the efficacy of aPL, which was greater than that from Eu-s/PTX because of the biomimetic property